Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from RETRACTED: Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. Local targets link to admitted publications; unresolved targets remain external evidence.
"What else can we do?"-Provider perspectives on treatment-resistant depression in late life
10.1111/jgs.17592 · 2022 · External reference
Diagnosing depression in older adults in primary care
10.1056/nejmp1311047 · 2014 · External reference
What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials
10.1016/j.euroneuro.2007.03.009 · 2007 · External reference
Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies
10.1192/bjp.bp.112.118307 · 2013 · External reference
Depression and risk of developing dementia
10.1038/nrneurol.2011.60 · 2011 · External reference
Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis
10.1001/archpsyc.63.5.530 · 2006 · External reference
The impact of depression on the well-being, disability and use of services in older adults: a longitudinal perspective
10.1034/j.1600-0447.2002.10078.x · 2002 · External reference
The association of late-life depression and anxiety with physical disability: a review of the literature and prospectus for future research
10.1097/00019442-200105000-00004 · 2001 · External reference
The impact of treatment-resistant depression on health care utilization and costs
10.4088/jcp.v63n1102 · 2002 · External reference
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression
10.1056/nejmoa2204462 · 2023 · External reference
Efficacy, safety, and tolerability of augmentation pharmacotherapy with Aripiprazole for treatment-resistant depression in late life: a randomized, double-blind, placebo-controlled trial
10.1016/s0140-6736(15)00308-6 · 2015 · External reference
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
10.1001/jama.2017.8036 · 2017 · External reference
Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study
10.1097/jcp.0000000000000663 · 2017 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
10.1186/1471-2288-14-135 · 2014 · External reference
Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
10.1177/0962280216669183 · 2018 · External reference
Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions
2019 · External reference
Quantifying heterogeneity in a meta-analysis
10.1002/sim.1186 · 2002 · External reference
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial
10.4088/jcp.18m12294 · 2018 · External reference
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report
10.1002/da.23114 · 2021 · External reference
The effect of treatment as usual on major depressive disorder: A meta-analysis
10.1016/j.jad.2016.12.013 · 2017 · External reference
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
10.1177/0269881115581093 · 2015 · External reference
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3
2016 · External reference
THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS
10.1002/da.22378 · 2015 · External reference
